More Evidence Needed For Chiesi’s Ultra Orphan Lamzede, Says NICE
Executive Summary
Chiesi still has work to do to convince NICE that its ultra rare disease treatment Lamzede is a cost-effective treatment.
You may also be interested in...
Anticancers, Orphans & The First CAR-Ts: New EU Drug Approvals In 2018
New approvals in the EU were again dominated by oncology drugs in 2018, although medicines for infectious diseases were a close second. The number of orphan drugs more than doubled over the previous year, to 17. There were also some star arrivals in multiple sclerosis, genetic disorders, metabolism and migraine.
EU New Drug Approvals 2018: Anticancers, Orphans, The First CAR-Ts – And More
New drug approvals in the EU were again dominated by oncology in 2018, although medicines for infectious diseases came a close second. The number of orphan drugs more than doubled over the previous year, to 17. There were also some key new arrivals in the areas of multiple sclerosis, genetic disorders, metabolism and migraine.
What’s Next After 20 Years Of NICE?
Meindert Boysen, head of NICE’s Centre For Health Technology Evaluation, shares advice for companies aiming to get their medicine to patients. His golden rules: engage in early advice and be more realistic about pricing.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports